Related Experiment Video
Updated: Jul 1, 2025

In Vivo Immunogenicity Screening of Tumor-Derived Extracellular Vesicles by Flow Cytometry of Splenic T Cells
Published on: September 23, 2021
Extracellular Vesicles as Novel Diagnostic and Therapeutic Agents for Non-Melanoma Skin Cancer: A Systematic Review
Konstantinos Seretis1, Eleni Boptsi1, Anastasia Boptsi1
1Department of Plastic Surgery, Medical School, University of Ioannina, 45100 Ioannina, Greece.
Abstract:
Standard non-melanoma skin cancer (NMSC) treatment involves surgery, recently combined with chemotherapy or immunotherapy in cases of advanced tumors. EVs, including exosomes, are integral to carcinogenesis, and are found in NMSC releasing mediators impacting tumor progression. Nevertheless, the precise intercellular signaling role of NMSC-derived EVs remains unclear. This review aims to elucidate their potential role in NMSC diagnosis and treatment. This systematic review encompassed literature searches in electronic databases from inception to September 2023, based on certain inclusion and exclusion criteria, addressing NMSC-derived EVs, their molecular cargo, and their implications in the diagnosis, prognosis, and treatment of NMSC. Key components were identified. Extracellular vesicle (EV) proteins and RNA have emerged as diagnostic biomarkers in EV-based liquid biopsy. Circular RNA CYP24A1, known for its molecular stability, holds promise as a diagnostic biomarker. Long noncoding RNAs (lincRNA-PICSAR) and Desmoglein 2 (DSg2) are linked to drug resistance, serving as prognostic biomarkers. EV mediators are being actively investigated for their potential role as drug delivery agents. In conclusion, this systematic review showed that NMSC-derived EVs display promise as therapeutic targets and diagnostic biomarkers. Further research is imperative to fully comprehend EV mechanisms and explore their potential in cancer diagnosis and treatment.
Insights
Non-melanoma skin cancer (NMSC) derived extracellular vesicles (EVs) show potential as diagnostic biomarkers and therapeutic targets. Further research is needed to understand their role in NMSC progression and treatment.
Area of Science:
- Oncology
- Biochemistry
- Cell Biology
Background:
- Standard non-melanoma skin cancer (NMSC) treatments include surgery, chemotherapy, and immunotherapy for advanced cases.
- Extracellular vesicles (EVs), including exosomes, play a role in cancer development and are found in NMSC, releasing mediators that influence tumor progression.
- The exact intercellular signaling function of NMSC-derived EVs is not fully understood.
Approach:
- This systematic review analyzed literature from database inception to September 2023.
- Inclusion and exclusion criteria were applied to studies focusing on NMSC-derived EVs, their molecular cargo, and their diagnostic, prognostic, and therapeutic implications.
- Key molecular components within NMSC-derived EVs were identified.
Key Points:
- EV proteins and RNA show promise as diagnostic biomarkers for NMSC through liquid biopsy.
- Circular RNA CYP24A1 is a stable diagnostic biomarker candidate.
- Long noncoding RNAs (lincRNA-PICSAR) and Desmoglein 2 (DSg2) are prognostic biomarkers linked to drug resistance.
- EV mediators are being explored as potential drug delivery agents.
Conclusions:
- NMSC-derived EVs represent promising therapeutic targets and diagnostic biomarkers.
- Further investigation into EV mechanisms is crucial for advancing NMSC diagnosis and treatment strategies.
Related Concept Videos
Overview of Exosomes
Stahl et al. discovered exosomes in 1983, but the exosomes were initially considered waste products released from the...
Clinical Applications of Epidermal Stem Cells
Skin Cancer
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...

